Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gemcitabine in Combination With the Oral Irreversible ErbB Inhibitor Afatinib Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial

NCT01728818 is registered in ClinicalTrials.gov with PD Dr. med. Volker Heinemann as lead sponsor.

NCT NCT01728818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01728818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gemcitabine in Combination With the Oral Irreversible ErbB Inhibitor Afatinib Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial
Lead sponsor
PD Dr. med. Volker Heinemann
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2013
Completion date
January 31, 2018
Enrollment
119 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

focus of study instead